William Blair analyst Max Smock has reiterated their bullish stance on IQV stock, giving a Buy rating on July 18.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Max Smock has given his Buy rating due to a combination of factors including IQVIA’s strong second-quarter financial performance, which exceeded expectations in several key areas. The company reported higher-than-anticipated revenue, adjusted EBITDA, and adjusted EPS, driven by favorable foreign exchange impacts and solid performance across its segments, particularly in TAS and R&DS.
IQVIA’s net book-to-bill ratio also surpassed targets, indicating robust demand in its clinical services. Management’s positive outlook on the clinical demand environment, with improved forward-looking indicators and strong RFP flow, further supports this optimistic view. Additionally, the TAS segment’s revenue growth reached the upper end of the company’s target range, showcasing the company’s operational strength and potential for continued growth.
According to TipRanks, Smock is an analyst with an average return of -20.0% and a 33.33% success rate. Smock covers the Healthcare sector, focusing on stocks such as Simulations Plus, Medpace Holdings, and Charles River Labs.
In another report released on July 18, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $180.00 price target.